A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study
- Autores: Silvia Antolín Novoa, Ramón Mel Lorenzo, Manuel Ramos Vázquez, Concepción Almanza, Lourdes Calvo Martínez, Elena Álvarez, A. González, Jesús García Mata
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 13, Nº. 9, 2011, págs. 686-691
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Introduction The objective was to evaluate a dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide (AC) as neoadjuvant treatment for patients with locally advanced breast cancer.
Patients and methods Ninety-nine patients were included and received 100 mg/m2 of docetaxel every two weeks for four cycles followed by 60 mg/m2 of doxorubicin and 600 mg/m2 of cyclophosphamide every two weeks for four cycles. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was administered systematically to all patients.
Results Efficacy and toxicity analyses were carried out on an intention-to-treat basis. After treatment, complete pathological response in the breast and lymph nodes was confirmed in 15 patients (15%, 95% confidence interval [CI]: 8.4�22.9). Clinical response rate was 74% (95% CI: 65�82), of which 19% were complete responses. Breastconserving surgery could be performed in 41% of patients. The dose-dense schedule was generally well tolerated. The most important grade 3/4 toxicities per patient were cutaneous toxicity (12.1%) and hepatic dysfunction (9.1%) during docetaxel administration, and neutropenia (28.1%) and leucopenia (8.3%) with AC.
Conclusion A dose-dense schedule of docetaxel followed by AC as neoadjuvant treatment is an effective and safe treatment for locally advanced breast cancer. Primary prophylaxis with G-CSF, and possibly the change in the sequence of drug administration, appears to play a major role in avoiding the excessive toxicity of dose-dense schedules.
